loading

Marker Therapeutics Inc 주식(MRKR)의 최신 뉴스

pulisher
Jun 17, 2025

Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Marker Therapeutics Announces Collaboration with Cellipont Bioservices for cGMP Manufacturing of MT-601 T Cell Therapy - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Marker Therapeutics and Cellipont Bioservices Announce - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Marker's Breakthrough Lymphoma Treatment Hits 78% Response Rate, Secures Major Manufacturing Deal - Stock Titan

Jun 17, 2025
pulisher
Jun 15, 2025

Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Invests $31,000 in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Purchases Shares of 15,326 Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World

Jun 15, 2025
pulisher
Jun 11, 2025

Brookline Capital sets $4 target on Marker Therapeutics stock - MSN

Jun 11, 2025
pulisher
Jun 05, 2025

Marker Therapeutics Reports Q1 2025 Financial Results - TipRanks

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Buys 21,703 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 03, 2025
pulisher
May 29, 2025

Transcript : Marker Therapeutics, Inc.Special Call - marketscreener.com

May 29, 2025
pulisher
May 26, 2025

Peptide Cancer Vaccine Market Detailed In New Research Report - openPR.com

May 26, 2025
pulisher
May 25, 2025

Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells - MSN

May 25, 2025
pulisher
May 20, 2025

Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma - OncLive

May 20, 2025
pulisher
May 20, 2025

MRKR: Promising Results from Phase 1 APOLLO Study on Lymphoma Treatment | MRKR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Marker Therapeutics Reports that Lymphodepletion Improves - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough: Marker's Cancer Treatment Achieves 78% Response Rate in Lymphoma Patients After CAR-T Failure - Stock Titan

May 20, 2025
pulisher
May 20, 2025

MRKR FY2028 EPS Reduced by Brookline Capital Management - Defense World

May 20, 2025
pulisher
May 19, 2025

Marker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming Webcast - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Leading Cancer Experts Reveal How MAR-T Technology Could Revolutionize CAR-T Cell Therapy Limitations - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Marker Therapeutics to Spotlight Multi-Antigen Recognizing - GlobeNewswire

May 19, 2025
pulisher
May 15, 2025

Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 14, 2025

Hematopoietic stem cell transplantation Market: Investment - openPR.com

May 14, 2025
pulisher
May 14, 2025

Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com

May 14, 2025
pulisher
May 14, 2025

Marker Therapeutics (MRKR) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 07, 2025

Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com

May 07, 2025
pulisher
May 03, 2025

Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World

May 03, 2025
pulisher
May 01, 2025

Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer - PR Newswire

May 01, 2025
pulisher
Apr 30, 2025

Marker Therapeutics Advances T Cell Therapies in 2024 - TipRanks

Apr 30, 2025
pulisher
Apr 29, 2025

LPL Financial LLC Acquires New Holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com

Apr 28, 2025
pulisher
Apr 26, 2025

MRKR stock touches 52-week low at $2.4 amid challenging year - MSN

Apr 26, 2025
pulisher
Apr 23, 2025

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - ADVFN

Apr 23, 2025
pulisher
Apr 10, 2025

Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow

Apr 10, 2025
pulisher
Apr 09, 2025

FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals

Apr 09, 2025
pulisher
Apr 04, 2025

Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com

Apr 04, 2025
pulisher
Apr 04, 2025

Brookline Capital Management Comments on MRKR Q1 Earnings - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Marker Therapeutics (NASDAQ:MRKR) Receives Strong-Buy Rating from WBB Securities - The AM Reporter

Apr 03, 2025
pulisher
Apr 03, 2025

Brookline Capital Management Estimates MRKR FY2026 Earnings - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Marker Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

MRKR stock touches 52-week low at $1.12 amid market challenges - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

Revolutionary MAR-T Cell Therapy: Marker CEO Reveals Latest Advances in Solid Tumor Treatment - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding - TipRanks

Mar 31, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):